Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1ICF

CRYSTAL STRUCTURE OF MHC CLASS II ASSOCIATED P41 II FRAGMENT IN COMPLEX WITH CATHEPSIN L

1ICF の概要
エントリーDOI10.2210/pdb1icf/pdb
分子名称PROTEIN (CATHEPSIN L: HEAVY CHAIN), PROTEIN (CATHEPSIN L: LIGHT CHAIN), PROTEIN (INVARIANT CHAIN), ... (5 entities in total)
機能のキーワードcysteine proteinase, cathepsin, mhc class ii, invariant chain, thyroglobulin type-1 domain, hydrolase
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数6
化学式量合計62721.42
構造登録者
Guncar, G.,Pungercic, G.,Klemencic, I.,Turk, V.,Turk, D. (登録日: 1999-01-07, 公開日: 2000-01-12, 最終更新日: 2024-10-30)
主引用文献Guncar, G.,Pungercic, G.,Klemencic, I.,Turk, V.,Turk, D.
Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
EMBO J., 18:793-803, 1999
Cited by
PubMed Abstract: The lysosomal cysteine proteases cathepsins S and L play crucial roles in the degradation of the invariant chain during maturation of MHC class II molecules and antigen processing. The p41 form of the invariant chain includes a fragment which specifically inhibits cathepsin L but not S. The crystal structure of the p41 fragment, a homologue of the thyroglobulin type-1 domains, has been determined at 2.0 A resolution in complex with cathepsin L. The structure of the p41 fragment demonstrates a novel fold, consisting of two subdomains, each stabilized by disulfide bridges. The first subdomain is an alpha-helix-beta-strand arrangement, whereas the second subdomain has a predominantly beta-strand arrangement. The wedge shape and three-loop arrangement of the p41 fragment bound to the active site cleft of cathepsin L are reminiscent of the inhibitory edge of cystatins, thus demonstrating the first example of convergent evolution observed in cysteine protease inhibitors. However, the different fold of the p41 fragment results in additional contacts with the top of the R-domain of the enzymes, which defines the specificity-determining S2 and S1' substrate-binding sites. This enables inhibitors based on the thyroglobulin type-1 domain fold, in contrast to the rather non-selective cystatins, to exhibit specificity for their target enzymes.
PubMed: 10022822
DOI: 10.1093/emboj/18.4.793
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2 Å)
構造検証レポート
Validation report summary of 1icf
検証レポート(詳細版)ダウンロードをダウンロード

251422

件を2026-04-01に公開中

PDB statisticsPDBj update infoContact PDBjnumon